Zenser T V, Mattammal M B, Brown W W, Davis B B
Kidney Int. 1979 Dec;16(6):688-94. doi: 10.1038/ki.1979.184.
The renal inner medulla may be exposed to high concentrations of organic compounds which are excreted into the urine. This report examines the capacity of the inner medulla to metabolize organic compounds both in vitro and in vivo. The compounds used were 1,3-diphenylisobenzofuran (DPBF), luminol, and benzidine. The inner medulla was shown to possess the capacity to oxidize each of these compounds. Microsomal oxygenation did not require NADPH. Cytochorome P-450 inhibitors carbon monoxide and metyrapone did not reduce DPBF metabolism. Lipoxygenase activity was not detected in inner medullary microsomes. Oxygenation of DPBF was demonstrated in inner medullary slices and was inhibited by indomethacin. The product of DPBF metabolism in renal slices and microsomes was identified as O-dibenzoylbenzene. In vivo experiments demonstrated benzidine metabolism, which was blocked by meclofenamic acid. On the basis of substrate specificity and inhibitor studies, it was concluded that oxygenation of DPBF, luminol, and benzidine was mediated by prostaglandin cyclooxygenase. These results are compatible with cooxygenation being a mechanism of inner medullary drug metabolism.
肾内髓质可能会接触到高浓度排泄到尿液中的有机化合物。本报告研究了内髓质在体外和体内代谢有机化合物的能力。所用的化合物为1,3 - 二苯基异苯并呋喃(DPBF)、鲁米诺和联苯胺。结果表明,内髓质具有氧化这些化合物的能力。微粒体氧化不需要NADPH。细胞色素P - 450抑制剂一氧化碳和甲吡酮并不降低DPBF的代谢。在内髓质微粒体中未检测到脂氧合酶活性。在肾内髓质切片中证实了DPBF的氧化,且吲哚美辛可抑制该氧化过程。肾切片和微粒体中DPBF代谢的产物被鉴定为O - 二苯甲酰苯。体内实验证实了联苯胺的代谢,甲氯芬那酸可阻断该代谢过程。基于底物特异性和抑制剂研究,得出结论:DPBF、鲁米诺和联苯胺的氧化是由前列腺素环氧化酶介导的。这些结果与共氧化作为内髓质药物代谢的一种机制相符。